Skip to Main Content

Henry S. Park, MD, MPH

Assistant Professor of Therapeutic Radiology; Associate Director, Residency Training Program, Therapeutic Radiology; Chief, Thoracic Radiotherapy Program, Therapeutic Radiology

Research Summary

As a radiation oncologist and epidemiologist, my research focuses on evaluating determinants of population-based outcomes, health services utilization, and medical decision-making for patients with cancer. I have used national and institutional observational databases as well as systematic reviews and meta-analyses to gain insight into how clinical, demographic, and health system factors affect quality of care and outcomes for this vulnerable population. I also highly prioritize the use of innovative statistical methods to minimize the inherent biases of retrospective analysis, having led the development of a tool known as sequential landmark analysis to control for immortal time bias when interpreting observational analyses studying the survival impact of adjuvant radiation therapy.

I have co-authored over 100 peer-reviewed original research articles, reviews, and chapters. I also direct the Yale Radiation Oncology Consortium (YROC) and collaborate closely with the Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center (COPPER). I am also interested in mentoring medical students and residents in comparative effectiveness and health services research, especially in projects relating to lung cancer and head and neck cancer.

Extensive Research Description

Population-based Outcomes; Health Services Utilization

Coauthors

Research Interests

Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Radiation; Small Cell Lung Carcinoma; Mentoring

Selected Publications

Clinical Trials

ConditionsStudy Title
LungMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
LungPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Urinary BladderPhase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)
PancreasPhase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
Esophagus; Larynx; Lip, Oral Cavity and PharynxA Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA
LungA Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Other SkinA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Breast - Female; BreastTAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Larynx; Lip, Oral Cavity and PharynxA Phase I Study of M6620 (VX-970) in Combination With Cisplatin and XRT in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
ProstatePhase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Larynx; Lip, Oral Cavity and PharynxPhase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Larynx; Lip, Oral Cavity and PharynxRadiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer
Lip, Oral Cavity and PharynxIndividualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA